The first human subject in a Phase 1 clinical study for a potential Ebola vaccine recently received a booster dose of Bavarian Nordic's MVA-BN Filo vaccine.
Researchers are testing MVA-BN Filo, which is meant to protect against Ebola Zaire, Ebola Sudan and Marburg virus, in conjunction with the cAd3-EBO Z vaccine developed by GlaxoSmithKline and the U.S. National Institutes of Health.
A previous study found that an MVA-based boost could provoke a stronger response from the immune system.
The current study includes 60 healthy adults divided into three groups, with each group receiving unique cAd3-EBO Z vaccine doses. Half of the adults will receive an extra dose of the MVA-BN Filo vaccine to boost their immune response.
Researchers will carefully monitor the subjects’ responses, especially the reactions of their humoral immune and cellular systems.
Bavarian Nordic is collaborating with Janssen Pharmaceuticals to further develop the MVA-BN vaccine.
“In support of the various clinical trials currently underway to fast-track the development of urgently needed vaccines against Ebola, we are pleased that these studies may confirm the role of a heterologous prime boost regimen incorporating the MVA-BN vaccine platform technology,“ Paul Chaplin, president and CEO of Bavarian Nordic, said.
The University of Oxford is sponsoring the trial study.